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Background: Dopamine agonist resistance in prolactinoma is an infrequent phenomenon. Doses of
cabergoline (CAB) of up to 2.0 mg/week are usually effective in controlling prolactin (PRL) secretion
and reducing tumor size in prolactinomas. The clinical presentation, management, and outcome of
patients that are not well controlled by such commonly used doses of CAB-resistant patients are poorly
understood.
Design and methods: A multicenter retrospective study was designed to collect a large series of resistant
prolactinoma patients, defined by uncontrolled hyperprolactinemia on CABR2.0 mg weekly.
Results: Ninety-two patients (50 F, 42 M) were analyzed. At diagnosis, most had macroprolactinomas
(82.6%); males were significantly older than females (PZ0.0003) and presented with a more
aggressive disease. A genetic basis was identified in 12 patients. Thirty-six patients (39.1%) received
only medical therapy, most underwent surgery (60.9%, including multiple interventions in 10.9%),
and 14.1% received postoperative radiotherapy. Eight patients developed late CAB resistance (8.7%).
The median maximal weekly dose of CAB (CABmax/w) was 3.5 mg (2.0–10.5). Despite a higher
CABmax/w in patients treated with multimodal therapy (PZ0.003 vs exclusive pharmacological
treatment), a debulking effect of surgery was shown in 14 patients, with a higher rate of PRL control
(PZ0.006) and a significant reduction in CABmax/w (PZ0.001) postoperatively. At last follow-up
(median 88 months), PRL normalization and tumor disappearance were achieved in 28 and 19.9% of
the patients respectively, with no significant sex-related difference observed in CABmax/w or disease
control. Mortality was 4.8%, with four patients developing aggressive tumors (4.3%) and three a
pituitary carcinoma (3.3%).
Conclusion: CAB-resistant prolactinomas remain a serious concern. Surgical debulking, newer
therapeutic strategies, and early diagnosis of genetic forms could help to improve their outcome.
European Journal of Endocrinology 167 651–662Introduction
The clinical prevalence of pituitary adenomas (PAs) is
w1:1000 of the general population (1). Prolactinomas
account for 40–60% of all PA; they occur usually in
females aged 20–50 years old and up to 80% present as
microadenomas (2). Although they are usually sporadic,ndocrinologyup to 5% of PA overall may present in a familial or genetic
setting such as multiple endocrine neoplasia type 1
(MEN1) and familial isolated PAs (FIPAs) (3, 4, 5).
Dopamine agonists (DA) are first-line therapy for
prolactinomas as they are effective in controlling
clinical symptoms, prolactin (PRL) levels and tumor
volume, while being well tolerated (2, 6). Because of itsDOI: 10.1530/EJE-12-0236
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cabergoline (CAB) has become the DA of choice in the
last 15 years. It has proved to be more effective and
better tolerated than bromocriptine, permitting PRL
normalization in 90% of prolactinoma patients with
microadenomas and in 80% with macroadenomas at a
median weekly dose of w1.0 mg (7, 8). Significant
tumor shrinkage also occurs in up to 70–90% of
patients over a 12–24 months period of CAB treatment,
with complete tumor disappearance in about 40 and
10% of micro- and macroadenomas respectively (8).
A minority of patients do not respond satisfactorily to
pharmacological treatment. Although no consensus
has yet been reached about the definition of pharma-
cological resistance to DA drugs, the most widely
accepted criterion is a failure to normalize PRL levels
(2, 6, 9), which can be associated with a lesser degree of
tumor shrinkage. In a large study on dose–response
relationships in prolactinoma patients with macroade-
nomas receiving CAB as first-line treatment, disease
control was obtained by a weekly dose of !1.5 mg in
most patients (O80%) (10).
Most studies to date have dealt with populations that
are responsive to CAB therapy, and there have been
relatively few on prolactinoma patients who are resistant
to DA therapy. To better understand this population, we
performed a multicenter, retrospective study to charac-
terize the clinical presentation and evolution of a large
group of patients with prolactinomas who did not
experience PRL normalization despite treatment with
CAB using at least the maximum dose used in the placebo
and active controlled trials of CAB during its registration,
which led to the usual maximal labeled dose of
2.0 mg/week (11, 12). We aimed to better define the
practical clinical characteristics of such cases and to
evaluate their evolution and prognosis in order to
provide insights on improved clinical management.Materials and methods
Clinical data
Prolactinoma patients with non-normalized PRL
secretion and with associated insufficient clinical symp-
tom/sign control on a minimal weekly CAB dose of
2.0 mg were identified at 12 centers (CHU Lie`ge, Belgium;
Assistance Publique-Hopitaux de Paris CHU Kremlin-
Biceˆtre, France; Neuromed Institute, Pozzilli, Italy; Federal
University of Recife, Brazil; CHU de Lyon, France; Federal
University of Brasilia, Brazil; CHU La Timone Marseille,
France; CHU Bordeaux, France; CHU Reims, France;
Ospedale Valdese, Turin, Italy; Ospedale Maggiore Milano,
Italy; CHU Larrey Toulouse, France). Such patients were
designated as being ‘resistant’ to the hormone-lowering
effects of CAB. Late resistance was defined by an
escape of pharmacological treatment after initial PRL
normalization in compliant patients. Anonymized patientwww.eje-online.orginformation was collected via a questionnaire that
included epidemiological, clinical, hormonal, and radio-
logical data on the patient, the tumor characteristics,
and the responses to therapy. PRL levels were determined
by commercial assays at each center but were unavailable
at diagnosis in five patients because of emergency surgery
and/or due to an unrecognized hook effect. Macro-
prolactin was assessed in all patients and was not found
to be the cause of elevated PRL in any of the cases. PAs
were classified into micro- and macroadenomas according
to their maximal diameter, and a classification of giant
adenomas (R40 mm) was also included. Invasion of
adjacent structures (cavernous sinus, sphenoid sinus, and
bone) was defined macroscopically according to neuro-
radiological imaging and/or intra-operative findings.
Compliance with prescribed therapy was assessed by
direct patient interview.
A total of 92 prolactinoma patients treated with
CAB met the criteria for the study. Although the first
diagnosis of prolactinoma was made over the period
1973–2010 (median: 1999), CAB began to be used from
late 1997 to early 1998. CAB was therefore given as
first-line treatment in 31 patients, whereas 54 patients
had received previous DA drugs either alone (nZ41)
or in combination with either surgery (nZ7) or surgery
followed by radiotherapy (nZ6). A further seven
patients had undergone previous initial surgery. Median
duration of follow-up from diagnosis was 88.5 months
(range 8–408).
As this was a retrospective study, no systematic
genetic analysis was performed. However, information
on genetic or familial diagnosis was systematically
sought from patient files (MEN1, Carney complex, FIPA,
or McCune–Albright syndrome).Statistical analysis
Statistical analysis was performed using the Statview
5.1 Software for PC (SAS Institute, Cary, NC, USA).
Nonparametric tests were used for comparison of
continuous values, using the Mann–Whitney and
Wilcoxon rank tests for unpaired and paired two-
group analysis respectively, and the Kruskall–Wallis
test for multiple subgroups analysis. The c2-test was
used to compare percentages values. P values !0.05
were considered significant.Results
Characteristics at diagnosis
Prolactinomas that were hormonally resistant to
control up to a dose of 2.0 mg/week of CAB had a
mean prevalence of 3.4% of prolactinoma patients
across the study centers. Among the 92 resistant
prolactinoma patients, 50 were female and 42 were
male. The mean age at diagnosis was 32.0G16.1 years.
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these, 15 patients had giant adenomas. The majority
of tumors were invasive at diagnosis (51.7%), and
among macroadenomas, invasion occurred in 60.8% of
cases. Neurological symptoms were frequent (54.9%).
Endocrine symptoms were very common (93.4%) but
complete hypopituitarism was rare (10.9%). Details are
summarized in Table 1.
Significant gender-related differences were noticed.
Men were older than women (PZ0.0003) and had
significantly higher PRL levels at diagnosis (P!0.0001;
Fig. 1). Macroadenomas were significantly more
frequent in men than women (PZ0.003), with
microadenomas being typically diagnosed in women
(14/15) and giant adenomas occurred mainly in men
(12/15). Neurological symptoms were significantly
more frequent in men (87.8 vs 28.0% in women,
P!0.0001); four men (9.5%) presented as acute
medical emergencies due to hydrocephalus/raised
intracranial pressure (nZ3) or pituitary apoplexy
(nZ1). Complete hypopituitarism at diagnosis was
significantly more frequent in men (19.0 vs 4.0% in
women, PZ0.021).Table 1 Clinical characteristics of 92 patients with resistant prolactino
All
Number of patients 92
Mean age at diagnosis (years; range) 32.0G16.1 (9–86)
AgeR50 years (%) 14 (15.2%)
Endocrine symptomsA 85/91 (93.4%)
Pubertal delay/1 amenorrhea 9 (9.9%)
Secondary hypogonadism 69 (75.8%)
HypopituitarismC 21 (23.1%)
MPHD 10 (11.4%)

















First-line CAB treatment 31 (33.7%)
Treatment received before CAB
DA alone 41 (44.6%)
Surgery alone 7 (7.7%)
SurgeryCDA 7 (7.7%)
SurgeryCDACRTx 6 (6.5%)
AUnavailable in one patient; Bgalactorrhea was associated with menstrual ab
dysfunction other than hypogonadism; ED, erectile dysfunction; MPHD, multipl
aUnavailable in one patient.
bUnavailable in three patients.
cUnavailable in five patients.
dUnavailable in nine patients.Pharmacological treatment with CAB
CAB was given as a first-line treatment in 31 patients
(33.7%), whereas the majority had received previous
therapeutic approaches (predominantly other DA)
(Table 1). A significant evolution in the choice of first-
line treatment was observed over time (P!0.0001),
with an increasing use of first-line DA, mainly
represented by CAB over the last decade (Fig. 2).
The mean maximal weekly dose of CAB (CABmax/w) was
4.1G1.7 mg (median 3.5, range 2.0–10.5) and was
similar in men and women (data not shown). Patients
who received CAB as a first-line treatment did not
significantly differ from others in terms of age, gender,
PRL values, or tumor volume at diagnosis (data not
shown). Although median pre-CAB PRL values were
higher in patients who received CAB as a first-line option
than in other patients (741.7 vs 155.0 ng/ml respectively,
PZ0.0034), the median CABmax/w was similar in both
groups (3.5 mg).
Eight patients (8.7%) developed late resistance
following an initial response to CAB (nZ1) or other
DA (nZ7). Most had macroadenomas (7/8), half were
invasive, and none had received prior radiotherapy.mas.
Male (M) Female (F) P
42 50
38.8G17.6 (9–86) 26.6G12.2 (11–65) 0.0003
11 (26.2%) 3 (6.0%) 0.0072
36/41 (87.8%) 49/50 (98.0%) NS
3 (7.1%) 6 (12.0%)
29 (69.0%) 40 (80.0%)
24 Hypogonadism 33 28 Amenorrhea
5 isolated EDA 7 oligomenorrhea
27 GalactorrheaB
15 (35.7%) 6 (12.0%) 0.020
8 (19.0%) 2 (4.0%) 0.021


















12 (28.6%) 19 (38.0%) NS
NS
21 (50.0%) 20 (40.0%)
4 (9.5%) 3 (6.0%)
4 (9.5%) 3 (6.0%)
1 (2.4%) 5 (10.0%)
normalities in all patients; Chypopituitarism refers to at least one pituitary





































































Figure 1 Demographic characteristics and PRL at diagnosis in
patients with resistant prolactinomas. (A) Age and sex (A1, box plot
and A2, distribution); (B) PRL (B1, box plot and B2, distribution).
Asterisks denote outliers.
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men (11.9 vs 6.0% in women, PZNS), and patients
were similar to those affected by primary resistance in
terms of age, PRL, and tumor characteristics at
diagnosis (data not shown). Median CABmax/w was
3.5 mg regardless of early/late resistance.1970








Figure 2 Evolution of first-line treatment in prolactinoma patients.
CAB, cabergoline; DA, dopamine agonist.Surgery in resistant prolactinomas
Fifty-six patients (60.9%) were operated on during the
study period (48 macro- and eight microadenomas),
including 15 patients undergoing first-line surgery
(16.3%). Initial characteristics of patients who under-
went first-line surgery were similar to those who did
not (data not shown) and none of those treated
surgically as first-line treatment was controlled post-
operatively. Overall, 74 surgical interventions were
performed (one surgery, nZ46 patients; two surgeries,
nZ5 patients; three surgeries, nZ3 patients; four
surgeries, nZ1 patients; and five surgeries, nZ1
patients), including spinal surgery for dural metastasis
in a patient with a malignant prolactinoma (see below).
Median PRL values decreased significantly from
540 ng/ml (range: 15.6–12 672) before surgery to
161 ng/ml (range: 0.0–10 850) after surgery
(P!0.0001). However, the rate of postoperative PRL
normalization was low overall (7.8%).
We therefore wished to further evaluate the contri-
bution of surgery in subsequent disease control.
Excluding patients who received previous radiotherapy,
a significant effect of surgical debulking could be shown
in 14 patients who received CAB before and after
noncurative surgery. As shown in Fig. 3, median PRL
levels significantly decreased on preoperative CABwww.eje-online.orgtreatment (PZ0.002 vs PRL at diagnosis). After
surgery, significantly lower PRL values were obtained
(PZ0.0012 vs PRL at diagnosis and PZ0.006 vs
preoperative PRL respectively) at significantly lower
weekly CAB dose (PZ0.001 vs preoperative). Excluding
one patient with uncontrolled disease requiring further
surgery and radiotherapy, median PRL levels at last
follow-up were further decreased (PZ0.006 vs post-
operative values), with three patients reaching normal
PRL values, and CABmax/w was further reduced as
compared with the postoperative values (PZ0.028).Long-term follow-up
The outcome of resistant prolactinomas was evaluated
at last follow-up in terms of PRL normalization and
tumor evolution, and results were analyzed according
to patients’ characteristics, follow-up, and treatment
schedule. Overall, DA was used exclusively in 36
patients (39.1%) or as part of multimodal treatment
including surgery in 43 patients (46.7%) or surgery
followed by radiotherapy in 13 patients (14.1%).
Median follow-up duration was significantly shorter in
patients treated by an exclusive pharmacological
approach as compared with multimodal treatment (60
vs 120 months respectively, PZ0.0007) but was similar
in irradiated and nonirradiated operated patients. The
mean CABmax/w significantly increased with treatment
complexity (3.4G1.2 mg in patients treated by DA
only, 4.3G1.8 mg in patients with surgery and DA,
and 5.5G2.0 mg in patients with DA, surgery, and
postoperative radiotherapy (PZ0.003)). Details on
the evolution of macroprolactinomas are provided
in Table 2.
Overall, 26/92 patients reached normal PRL levels
(28.3%). These include 8/36 patients treated by












































Figure 3 The debulking effect of transphenoidal surgery in 15 patients
with resistant PRL-secreting macroadenomas. (A) PRL values,
(B) CAB weekly dose. T0, PRL atdiagnosis;T1, minimumpreoperative
PRL; T2, postoperative PRL; T3, minimum PRL at last follow-up.
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exclusive DA). Although median PRL at diagnosis
was significantly lower in patients who normalized
at last follow-up than in those who did not (356.5
vs 915.0 ng/ml, PZ0.001), the rate of PRL normali-
zation was not significantly influenced by patients’
gender, tumor volume, primary/secondary resistance,
CABmax/w, or follow-up duration (data not shown).
Among patients with uncontrolled PRL at last follow-up
and available PRL at diagnosis (61 out of 66), aR50%
PRL decrease was obtained in most cases (72.1%),whereas 14.7% had a PRL decrease!50% and 13.1%
a further PRL increase.
Tumor disappearance was reported in 16/87 cases
(19%) and residual micro- and macroadenomas were
present at last imaging in 26.7 and 53.3% of the cases
respectively. Tumor disappearance tended to be more
frequent in microprolactinomas (35.7 vs 15.1% in
macroprolactinomas, PZ0.07) and in women (25 vs
10.2% in men, PZ0.08). Overall, 16/73 macro-
adenomas shrank to microadenomas (21.9%), one
microadenoma progressed into a macroadenoma
after pregnancy, and six tumors were still in progression
at last follow-up (6.9%).
We finally analyzed the modifications of CAB
schedule throughout follow-up. In patients who
reached normal PRL, the mean weekly CAB dose
could be progressively reduced from 4.5G1.9 mg
(median 3.5 mg) to 1.8G1.8 mg (median 1.25 mg)
at last follow-up (P!0.0001), with complete drug
withdrawal in seven patients (26.9%). The use of
multimodal therapy allowed a significant reduction in
CAB requirement (Fig. 4).High-dose CAB regimen
In order to evaluate the efficacy of exclusive high-dose
CAB regimen, a subgroup of 19 patients receiving at
least daily 0.5 mg CAB therapy (CAB R3.5 mg/week)
was analyzed separately. PRL normalization was
achieved in 5/19 patients (26.3%), with some degree
of tumor shrinkage in 10/19 (52.6%). None had
complete tumor disappearance and none had tumor
progression. Three patients (15.8%) had reduced
weekly CAB at last follow-up.Locally aggressive and malignant
prolactinomas
The mortality rate was 4.3%, due to pituitary
carcinomas (nZ2) or neurological complications of a
rapidly growing pituitary tumor (nZ2). Overall, three
patients developed a pituitary carcinoma and four had
locally aggressive tumors (Table 3). All patients had
macroadenomas at diagnosis and required surgery
(up to five times) and radiotherapy (up to four times).
High CABmax/w were used: 7.0 mg in all carcinoma
patients, 5.4G2.5 mg in those with aggressive
tumors. Temozolomide (TMZ) induced a significant
hormonal and tumor response in two carcinoma
patients (Table 3, patients 2 and 3): the first was
partially controlled but died of disease progression 1
year after TMZ withdrawal because of severe drug
intolerance. In the second patient (who had MEN1),
PRL near-normalization was obtained, which
remained stable after TMZ withdrawal. TMZ was
also successfully used in another MEN1 patient
(Table 3, patient 5), leading to PRL normalization,











CAB withdrawnCAB reducedCAB max
Figure 4 Evolution of CAB treatment in patients with resistant
prolactinomas.
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apy regimens induced only partial and transient
responses in three patients. Rapid tumor progression
in patient 6 was accompanied by PRL normalization
during the last follow-up period, suggesting tumor
de-differentiation.Genetic aspects
Five patients presented with clinical MEN1 disease
and three had FIPA. Germline MEN1 mutations were
found in 4/5 clinical MEN1 patients and an AIP
mutation in 1/3 FIPA patients. AIP sequencing was
also performed in 22 of the sporadic patients aged 9–60
years old at diagnosis, with three AIP mutations and one
variant of uncertain significance being found – all were
young patients (!20 years old) with invasive macro-
adenomas. Overall, a genetic/familial background wasTable 2 Outcome of patients with prolactin-secreting macroadenomas
outcome of 77 macroadenomas with sufficient radiological details at l
Macro-remnant Mi
n 46 16
Gender 28 M/18 F 7 M
Characteristics at diagnosis
Age 36.5G18.1 33
PRL (ng/ml)a 2560.0 (100.0–25 640.0) 81
Invasive tumorsb 30/41 (73.2%) 7/1
Treatment
DA/DACsurgery/RTxc 22/14/10 7/8
Multimodald 24/46 (52.2%) 7/1
CABmax (mg/week) 3.5 (2.0–10.5) 3.5
Outcome at last follow-up
Follow-up duration (months) 71.5 (8–408) 10
PRL (ng/ml) 170.9 (0.7–6098.0) 41
PRL normalization 9/46 (19.6%) 6/1
CAB at last follow-up 3.0 (0.0–7.0) 2.0
CAB withdrawal 4/46 (8.7%) 3/1
aUnavailable in five cases.
bUnavailable in five cases.
cRTx: radiotherapy – all irradiated patients also received surgical treatment.
dMultimodal therapy includes pharmacological treatment, surgery, and radiothe
www.eje-online.orgrecognized in 12 patients. All had macroadenomas and,
as compared with other patients, they were significantly
younger at diagnosis (23.2G13.7 vs 33.3G16.1 years
old, PZ0.021), received a significantly higher CABmax/w
(5.1G1.9 vs 3.9G1.7 mg, PZ0.013), and radiother-
apy was used more frequently (33.3 vs 11.2%, PZ0.04).Discussion
The concept of pharmacological resistance in prolacti-
nomas, empirically defined as a failure to normalize PRL
levels and/or reduce tumor volume by at least 50% (9),
has been refined in recent years, thanks to studies
focused on CAB-treated patients. Because of its greater
efficacy and tolerance, CAB has reduced the number of
patients unable to achieve PRL normalization because
of side effects that limit tolerance and compliance to
treatment (7, 8, 13). In addition, discrepancies bet-
ween the hormonal and tumor responses have lead
to tumor shrinkage being considered unsuitable to
define pharmacological resistance (8). Based on a recent
dose–response study on PRL-secreting macroadenomas
(14) and on current labeling dose ranges for CAB in
clinical practice (11, 12), we focused our attention on
patients who failed to normalize PRL at the upper end
of the labeled titration range for CAB in prolactinoma
treatment, namely 2.0 mg/week.
The first aim was to define the epidemiology of
such patients and the following characteristics were
observed: i) a large majority had macroadenomas
(O80%) and/or invasive tumors (O50%), indicating
that hormonal resistance is generally associated with
larger/more aggressive tumors. ii) An unusually high
proportion of patients were males and this genderuncontrolled byR2 mg/week of cabergoline. This table refers to the
ast follow-up.
cro-remnant No remnant P
11
/9 F 3 M/8 F 0.102
.2G15.6 25.7G12.4 NS
9.5 (182.8–4152.0) 207.0 (50.6–2800.0) !0.0001
6 (43.7%) 3/11 (27.3%) 0.009
/1 0/10/1 0.0048
6 (56.2%) 11/11 (100%) 0.013
(2.0–7.0) 3.5 (2.5–9.0) NS
3.0 (24–348) 108.0 (38–240) NS
.0 (6.3–291.2) 18.8 (4.4–1137.5) 0.126
6 (37.5%) 6/11 (54.5%) 0.048
(0.0–3.5) 0.75 (0.0–4.0) 0.016















treatments Chemotherapy Last follow-up





Multiple local recurrences with
progressively increasing
pharmacological resistance to
DA drugs, including CAB up to
7.0 mg/week at last follow-up
Five pituitary surgeries (four
TC, one TS), pituitary
RTx (five times), RTx for
bone metastasis (lumbar
vertebrae)
None Died from metastatic disease
in a palliative unit
PRL at last follow-up
45 500 ng/ml
PRL at diagnosis N/A
Metastasis diagnosed after
15 years of evolution in the
absence of pituitary remnant
Follow-up duration: 17 years
since initial diagnosis,
including 14 months since
carcinoma diagnosis
2 18/F Macroadenoma Carcinoma with
multiple dural
metastases
Multiple local recurrences with
a highly aggressive local
evolution starting 16 years
after initial diagnosis and
increasing pharmacological
resistance to DA drugs,
including CAB up to
7.0 mg/week
Four pituitary surgeries
(three TS, one TC),
ventriculo-peritoneal
shunt for hydrocephalus








complications in a palliative
unit
PRL at diagnosis N/A
Dural metastasis diagnosed
after 22 years of evolution




PRL at last follow-up
3114 ng/ml
Follow-up duration: 27 years
since initial diagnosis,









Highly aggressive local recur-
rence in a sporadic MEN1
patient






sisting after TMZ withdrawal
PRL 800 ng/ml Primary CAB resistance up to
7.0 mg/week
PRL at last follow-up: 80 ng/ml
Metastasis diagnosed after
10 years of evolution
Follow-up duration: 16 years
since initial diagnosis,






Highly aggressive Highly aggressive evolution with
invasion of the third ventricle,
hydrocephalus, diabetes
insipidus and hypopituitarism
One pituitary surgery (TS),
pituitary RTx (twice)
None Died from neurological
complications
PRL 4000 ng/ml Increasing resistance to DA
drugs, including CAB
3.0 mg/week




5 23/F Macroadenoma Highly aggressive Invasive regrowth 15 years after
first successful surgery,
followed by multiple recur-
rences in a familial MEN1
patient
Four pituitary surgeries
(four TS), pituitary RTx
TMZ (20 cycles) Marked shrinkage and PRL
normalization
PRL 350 ng/ml Increasing resistance to DA
drugs, including CAB up to
8.0 mg/week
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www.eje-online.orgimbalance increased with patients’ age at diagnosis.
There was a 1.5:1 female to male ratio before the age of
50 that inverted to a 3.7:1 male to female ratio
thereafter. This differs from unselected prolactinomas,
which are characterized by a 10:1 female to male ratio
before the age of 50, decreasing to 1:1 thereafter (2).
iii) Significant gender-related differences were found at
presentation, which are reminiscent of unselected
prolactinomas, with microadenomas being observed
almost exclusively in women and giant prolactinomas
preferentially occurring in men. Resistant prolactino-
mas in men were more frequently invasive and
presented with significantly higher PRL levels than in
women. Additionally, women were diagnosed w12
years earlier than men. These characteristics appear to
be quite distinct from the general experience with CAB
in the endocrine setting. In the large unselected
population reported by Verhelst et al., the proportion
of patients that required more than 2.0 mg/week of CAB
was !10%. As compared with those CAB-responsive
patients, the current study population had a higher
proportion of males (45.7 vs 22.4%), a higher
proportion of macroadenomas (83.7 vs 51.0%), and
hence, a more frequent reliance on surgery (60.9 vs
25.5%) and radiotherapy (14.1 vs 3.1%). The median
final dose used among the total population reported by
Verhelst et al. was !1.0 mg/week as compared with a
median final dose of 3.5 mg/week in the current study.
Interestingly, among patients who were considered
resistant to CAB in the Verhelst et al. study, the median
final CAB dose was also 3.5 mg/week. Although early
recognition of hyperprolactinemia is easier in women,
gender-related differences in prolactinoma growth
potential have been shown (14) and pharmacological
resistance was already reported more frequently in men
(10). iv) Genetic predisposition to PAs appeared as a risk
factor to develop pharmacological resistance. Indeed,
a genetic background was found in 12 patients, which
would represent 13% of the series but may be under
estimated due to the lack of systematic genetic analysis.
The contribution of MEN1 (5.4% clinical and 3.2%
genetic) is not surprising since prolactinomas are the
most common MEN1-related PAs and are more fre-
quently hormonally resistant than sporadic prolactino-
mas (3). Prolactinomas are also the most prevalent
phenotype in FIPA kindreds (4, 5), and a FIPA context
was recognized in 3.3% of our patients. Excluding
the intronic variant of uncertain significance, AIP
mutations were found in 1/3 FIPA patients and in 3/22
sporadic patients (13.6%). Such data are in agreement
with AIP mutations associated with aggressive prolacti-
nomas in FIPA and in young sporadic patients, with a
male predominance (15, 16, 17). Further studies are
necessary to better evaluate the prevalence of AIP
mutations in sporadic-resistant prolactinomas.
The biological basis of pharmacological resistance
remains poorly understood (9, 18). Research has
mainly focused on the D2R, reporting a reduced
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(20), impaired balance between its short and long
isoforms (21), and genetic polymorphisms (22).
Additional factors involved in the aggressiveness of
prolactinomas may interfere with D2R signaling or
exert opposing biological effects on lactotroph cells.
These include abnormalities in growth factors signaling
(18, 23) and in extracellular matrix components
(24, 25), the increased expression of genes involved in
cell proliferation (25, 26), and loss of tumor suppressor
genes at various loci (24). The promoting effects of
estrogens on prolactinoma formation are well known
(27), and gender-related differences in sex steroid
receptor expression, especially the estrogen receptors
(ERs), and in the steroid milieu, may contribute to the
aggressiveness of prolactinomas in men (28). Interest-
ingly, although estrogens induce dopamine resistance in
lactotrophs (27), ER does not appear to be differentially
expressed in resistant prolactinomas (20, 29), and most
prolactinomas in men respond to treatment (30). In the
current study, the maximal weekly CAB dose used was
similar in both sexes and the rate of PRL normalization
was not significantly higher in women. Complete
shrinkage tended to be more frequently observed in
women, even in macroadenomas, but macroadenomas
in men tended to be more aggressive. In particular, giant
adenomas often require high CAB doses to be controlled
(31). Further work is needed to better evaluate potential
gender-related differences in the tumor-shrinking
potential of CAB. Finally, the unusual proportion of
genetic forms strongly suggests that alterations in the
MEN1 and AIP genes are able to negatively impact the
pharmacological response in prolactinomas (3, 15, 32).
This is further supported by the higher CABmax doses
used in these patients.
The first recommended step in the treatment of
resistant prolactinomas is to switch to a more potent
DA where available, and CAB is currently the drug of
choice (6, 13). Where PRL fails to normalize at a 2.0 mg
CAB weekly dose, a stepwise dose increase is rec-
ommended, provided that each step improves PRL
secretion and/or disease-related symptoms (6, 31, 33).
Some authors failed to observe beneficial effects in
increasing CAB dose over 3.5 mg/week (6), whereas
others have reported successful increases up to 7.0 mg or
more (12, 31, 33, 34). In this study, the use of
pharmacological treatment alone was associated with
PRL normalization in 22% and tumor shrinkageO50%
of the cases. However, due to the retrospective character
of this study, the follow-up duration was shorter with
medical therapy alone than that with multimodal
treatment. Exclusive high-dose CAB regimen, which
was used in all but one participating center, proved to be
effective in a significant subset of patients, and represents
a valid option for those that do not respond to doses up to
2.0 mg/week.
Surgery is often necessary in prolactinomas resistant
to the maximal tolerated dose of DA (6, 33, 35). In ourseries, only 15 patients (16%) underwent first-line
surgery, which was replaced by first-line DA therapy
over time. Overall, 56 patients were operated on
(w60%), including nine patients (10%) who underwent
repeated surgery. Surgery helped by reducing tumor
mass, but postoperative PRL normalization was
obtained in a minority of cases (!10%, none after
first-line surgery). Remission rates up to 36% have been
reported in resistant prolactinomas, but most patients
achieving normal postoperative PRL had moderate
preoperative hyperprolactinemia (36). An important
finding of this study is the significant debulking effect of
surgery, which could be documented in a subgroup of
patients who received CAB before and after surgical
treatment, and experienced during their postoperative
follow-up a further significant reduction in PRL levels
while reducing their weekly CAB dose by 50%. This
finding extends the role of surgery in the endocrine
control of secreting adenomas (37). At last follow-up,
patients treated by combined surgical and pharma-
cological approaches achieved a rate of PRL normal-
ization and/or complete tumor shrinkage of 33.0 and
36.8% respectively, with a minority showing disease
progression (5.3%). Although no significant benefit of
postoperative irradiation was found in terms of PRL
normalization (30.8%) or complete tumor shrinkage
(!10%), the high CABmax/w used in this subgroup
confirms that radiotherapy was proposed for severely
resistant tumors. Indeed, radiotherapy is recommended
in patients who are uncontrolled by DA and surgery
with the main goal of controlling tumor growth (2, 30).
Its potential effects on PRL decline are delayed, PRL
normalization may not be achieved, and radiation-
induced hypopituitarism is frequent. Occasional but
severe neurological side effects or second tumors should
also be considered (38).
Severely resistant prolactinomas remain a major
therapeutic challenge. In this series the rate of
uncontrolled patients was remarkably high, with
O70% uncontrolled hyperprolactinemia, w15%
tumor progression during periods of follow-up on CAB
treatment, leading to highly aggressive tumors in 4.4%
and malignant evolution in 3.3%, with a disease-related
mortality rate of 4%. Malignancy was more frequent
than in unselected pituitary tumors, where it has been
reported in!0.5% (39). Of note, most highly aggressive
or malignant prolactinomas occurred in women, and
three occurred in the setting of MEN1. Malignant
transformation is generally a late event in pituitary
tumors, as supported by metastasis recognized in our
patients 10–22 years after the initial diagnosis of
prolactinoma. As reported herein, it is heralded by
multiple local recurrences, a progressive worsening of
the hypersecretory state, and an increasing degree of
pharmacological resistance (39), highlighting the need
for long-term close surveillance in such patients. An
appropriate use of extra-pituitary magnetic resonance
imaging (MRI) and/or nuclear imaging (39, 40) maywww.eje-online.org
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nomas and increase their clinical relevance. Various
chemotherapy regimens have been proposed (39), but
TMZ is becoming a mainstream choice (33, 41). In our
series, TMZ was successfully used in two carcinomas
and a highly aggressive prolactinoma. Tumors
showing reduced methylguanine-DNA methyltransfer-
ase expression may be more sensitive to TMZ (41), but
this finding is debatable and a 3-month trial is generally
able to identify TMZ responders (42). Observational
data on early chemotherapy associated with long-
lasting responses in pituitary carcinomas (39) support
the need for an early recognition of their metastatic
potential.
Few alternative pharmacological options are
available for resistant prolactinomas not requiring
chemotherapy. Excessive estrogen exposure (even via
testosterone replacement therapy in men) should be
avoided (13) and benefits of anti-estrogens or aromatase
inhibitors have been occasionally reported (2). Available
somatostatin analogs are poorly effective (43) but
encouraging in vitro data with SOM230 have been
reported (44). Animal models lacking the D2R may
be helpful to develop new strategies in resistant
prolactinomas (45).
An additional concern in resistant prolactinoma
patients is the long-term use of high CAB doses, which
has been associated with cardiac valve fibrosis in
Parkinson’s patients (46). Although several studies
performed in hyperprolactinemic and prolactinoma
patients indicate only modest valve dysfunction, if any
(47), a relationship between cardiac valve abnormalities
and the cumulative dose of CAB cannot be ruled out
entirely in all cases. Periodic echocardiography is
warranted in resistant prolactinoma patients and
potential reduction of CAB requirement by surgical
debulking could be considered.
In conclusion, this large series confirms that relative
pharmacological resistance to CAB defines a group of
patients with more aggressive disease and underlines
the potential risk of highly aggressive or malignant
evolution in severely resistant patients. It also supports
the potential role of genetic factors in determining
dopamine resistance and the benefits of debulking
surgery in terms of disease control and safety. Because
uncontrolled evolution remains largely unpredictable,
future research should focus on the early identification
of potentially aggressive tumors and alternative
pharmacological approaches.Declaration of interest
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